Advertisement
Seth Rotz, MD, joins the Cancer Advances podcast to share insights
More children are surviving childhood cancers than ever before. Each year in the United States about 15,000 children are diagnosed with cancer, and about 80% to 85% will survive five years or longer.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
While these numbers are encouraging, pediatric oncologists say a shift to better longer-term management of pediatric cancer survivors is warranted. The Childhood Cancer Survivorship Program at Cleveland Clinic Children’s is focused on doing just that.
Led by pediatric hematologist/oncologist Seth Rotz, MD, the physicians work with pediatric cancer survivors, their families, and other subspecialists as needed to identify risks and monitor late effects associated with disease and its treatment. They also provide counsel and resources related to other concerns, such as family planning and psychosocial issues.
Dr. Rotz joined the Cancer Advances podcast to discuss the goals of the program, the biggest issues in childhood cancer survivorship programs, and the next exciting thing in the field.
“Our focus in cancer survivorship has focused a great deal on the medical effects of having received chemotherapy and radiation. And, I think, in the last several years, there’s just been more attention focused on questions like: What are the long-term psychological impacts? What are the financial impacts of having had cancer? Does this impact whether a teenager ends up applying to college or not? Or does it put somebody in a position where they can’t change jobs because they’re worried about health insurance coverage and so forth,” he says.
“And then we have so many people and parents, too, who have some degree of post-traumatic stress from their treatment, and so we are trying to identify different mental health issues that can go along with treatment and get people plugged in with the resources they need, which is another very important part of what we do.”
Advertisement
Advertisement
Advertisement
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Findings from large database important to inform clinical practice
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant